<DOC>
	<DOC>NCT01714817</DOC>
	<brief_summary>The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)</brief_summary>
	<brief_title>Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching Service at 85556LUPUS. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Note: Subjects &gt; 16 are eligible for enrollment at selected centers Potential subjects must have active lupus nephritis Biopsy within 12 months prior to screening visit indicating active Class 3 or 4 proliferative lupus glomerulonephritis (lupus effecting your kidney) Urine protein creatinine ratio (UPCR) ≥ 1 at Screening Serum creatinine ≤ 3 mg/dL (ie, ≤ 265 micromol/L) There must also be evidence of active disease within 3 months of Screening, based on at least one of the following: Worsening of lupus nephritis OR UPCR ≥ 3 at Screening OR Active urine sediment OR Biopsy within 3 months prior to screening visit indicating active Class 3 or Class 4 active proliferative lupus glomerulonephritis Inclusion Criteria for the LongTerm Extension Period: Signed Written Informed Consent Subjects who achieve a complete or partial renal response after completing 2 years of doubleblind treatment Systemic Lupus Erythematosus (SLE) must be the primary/main autoimmune diagnosis Current symptoms of severe, progressive, or uncontrolled nonSLE related renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, or other concomitant medical conditions that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study Significant active Central nervous system (CNS) lupus with the exception of fatigue or mild stable cognitive Subjects who are diagnosed as endstage renal disease or whose kidney damage is too significant and irreversible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>